Abstract
Full text links
Read article at publisher's site: https://doi.org/10.1001/jamanetworkopen.2023.23316
Read article for free, from open access legal sources, via Unpaywall: https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2807196/gnther_2023_ic_230119_1688585784.31568.pdf
Citations & impact
This article has not been cited yet.
Impact metrics
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/151596512
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Lancet Infect Dis, 21(8):1107-1119, 24 Mar 2021
Cited by: 287 articles | PMID: 33773111 | PMCID: PMC7990482
Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis.
JAMA Netw Open, 5(1):e2143955, 04 Jan 2022
Cited by: 65 articles | PMID: 35040967 | PMCID: PMC8767431
Review Free full text in Europe PMC
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet, 397(10275):671-681, 02 Feb 2021
Cited by: 960 articles | PMID: 33545094 | PMCID: PMC7852454
Host factors and vaccine efficacy: Implications for COVID-19 vaccines.
J Med Virol, 94(4):1330-1335, 07 Dec 2021
Cited by: 41 articles | PMID: 34845730 | PMCID: PMC9015327
Review Free full text in Europe PMC